RxDoctor Payments Data

Anthony Henry, DO

Family Medicine · Fort Wayne, INNPI 1609867019

Payments from drug & device makers

$809in general payments, 2019–2025

Across 43 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$355
  • AstraZeneca$140
  • Lilly USA, LLC$133
  • GSK$55
  • Novo Nordisk$50
  • Merck$43
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$809100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$809 in reported general payments places this provider in the 55th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$40,323
Medicare patients
109
Services billed
476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide31$46,376
JardianceEmpagliflozin34$45,060
EliquisApixaban44$35,505
Tresiba Flextouch U-200Insulin Degludec22$25,791
Soliqua 100-33Insulin Glargine/Lixisenatide23$24,069
FarxigaDapagliflozin Propanediol32$23,636
XareltoRivaroxaban12$23,630
JanuviaSitagliptin Phosphate12$20,960
TradjentaLinagliptin11$14,972
VascepaIcosapent Ethyl14$10,210
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$2,900
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$2,774
Venlafaxine Hcl ErVenlafaxine Hcl18$2,580
Atorvastatin Calcium231$2,005
Levothyroxine Sodium253$1,871

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$17$60,03245 claims
Lilly USA, LLCMounjaro$133$46,37631 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$355$24,06923 claims
AstraZenecaFarxiga$140$23,63632 claims
MerckJanuvia$43$20,96012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →